Human cytomegalovirus (CMV) is the most common cause of congenital and perinatal infections throughout the world. The prevalence of congenital CMV infection varies widely between different populations (0.2-3.0%). Less than 5% of infants with congenital CMV infection have typical cytomegalic inclusion disease, another 5% have atypical involvement, and the remainder (90%) are asymptomatic at the time of delivery.' Even when asymptomatic at birth, 5--17% of infants with these asymptomatic congenital CMV infections will develop progressive sensorineural hearing loss or other neurodevelopmental difficulties within the first 4 years of life.
We have studied the incidence of congenital CMV infection in Japan. Of 7995 Japanese neonates, 31(0.39%) were identified as having congenital CMV infections on the basis of viruria at birth. Three of 31 infants had clinically severe disease resulting in death during the neonatal period. Prospective studies of children born with asymptomatic congenital CMV infection have also revealed a wide but significant spectrum of neurologic complications. A decrease in the prevalence of serum antibodies against CMV has been seen in recent years as a consequence of improvements in the social and economic conditions in Japan in the last 20 years.* From January to December 1988, serum samples were collected from 173 Japanese pregnant women who visited a hospital in Sapporo, Japan, at 32-36 weeks of gestation. Serum samples were also obtained from 345 pregnant women who visited the same hospital at the same stage of gestation during January 1999 to June 2000. Informed consent was obtained from those participating. CMV PCS (pipetted control system) Medac IgG and IgM test kits, kindly supplied by Medac Diagnostika, Hamburg, Germany, were used to detect serum IgG and IgM antibodies against CMV. All serum samples, from both 1988 and 1999-2000, were tested at the same time. Testing and interpretation of the results were performed according to the manufacturer's instructions.
Two hundred and thirty-five of 345 (68.1%) Japanese pregnant women at 32-36 weeks of gestation had IgG and seven (2.0%) had IgM antibodies to CMV in the years 1999-2000 in Sapporo, Japan, by enzyme immunoassay. One hundred and forty-seven of 173 (85.0%) sera had IgG and one (0.6%) had IgM antibodies in 1988. One hundred and sixty-one of 354 sera (46.7%) from the years 1999-2000 showed optical density (OD) titers of IgG antibody of more than 1.000. On the other hand, only three (1.7%) of 173 sera from 1988 showed OD infection.3 The presence of serum anti-CMV IgM antibody is also diagnostic evidence of primary or acute CMV infection, and may be seen with reactivation, along with IgG. Transmission of CMV by natural routes is important with respect to preventing CMV transmission to seronegative pregnant women. CMV is isolated more frequently from cervical secretions and semen than from urine and other clinical specimens. Viral titers in semen were reported to be 100 000 times greater than those in urine. Evidence for sexual transmission of CMV was provided by determining the prevalence of serum antibodies to CMV and viral shedding in male sex partners of women with and without CMV infection.4 However, it is also necessary to take into account other potential sources of CMV infection, including exposure to young children who are excreting CMV.
In certain countries, parental interest groups have called for screening programs for the general obstetric population in an attempt to reduce the rate of fetal damage with congenital CMV infection. The population of seropositive women of childbearing age in populations of low socio-economic status is about 85%, and that in populations of high socioeconomic status is about 55%. According to a previous report,5 more than 90% of the population in Japan was seropositive by 20 years of age. Primary CMV infection during pregnancy occurred in approximately 1% of susceptible women. Although social and economic conditions have improved dramatically, it was also reported that the prevalence of CMV had been stable during 1976-90.5 Since annual live births in Japan used to be approximately 1.22 million, 4000-5000 infants with congenital CMV infection were presumed to be born each year. From the results of the present study, cases of congenital CMV infection in Japan are considered to be increasing.
Understanding the epidemiology of CMV is a key element in the development of strategies for the prevention of congenital infection. The prevalence of serum antibodies to CMV was decreasing and primary CMV infection during pregnancy was speculated to be increasing in Sapporo, Japan during 1988-2000. Entirely new approaches to prevention and treatment of congenital CMV infection are necessary, including antiviral interventions and the development of a vaccine strategy.
